CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Chlorhexidine 2.5 mg +1 moredrug
Likely dose
Chlorhexidine 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01079663
NCT01079663Phase 2Completed

The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis

Dexcel Pharma Technologies Ltd.·interventional·Posted Mar 3, 2010·Updated Jun 15, 2021

In Brief

A Phase 2 clinical trial evaluating Chlorhexidine 2.5 mg and Placebo chip for Peri-implantitis. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 3, 2010
Enrollment StartMar 1, 2010
Primary CompletionOct 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.3 years ago

Interventions

Chlorhexidine 2.5 mgdrug

Placebo chipdrug